Theory Paper IIDrNB Cardiology – Theory Notes
ALCOHOL SEPTAL ABLATION; CURRENT STATUS
ICLINICAL INDICATIONS AND POSITION IN THE 2024 AHA/ACC & 2023 ESC ALGORITHM
- Core Concept: Alcohol Septal Ablation (ASA) (first performed by Ulrich Sigwart in 1994/1995) is a percutaneous catheter-based Septal Reduction Therapy (SRT) for Hypertrophic Obstructive Cardiomyopathy (HOCM) that infuses desiccated absolute (96 to 98 percent) ethanol into a target first or second septal perforator branch of the LAD to induce a localized, controlled basal interventricular septal infarction, resulting in basal septal akinesia/thinning, widening of the Left Ventricular Outflow Tract (LVOT), abolition of Systolic Anterior Motion (SAM) of the mitral valve, and reduction of SAM-mediated mitral regurgitation.
- Strict Hemodynamic and Clinical Prerequisites for Any Septal Reduction Therapy (Class I):
- Severe Drug-Refractory Symptoms: NYHA Functional Class III or IV exertional dyspnea, limiting angina, or recurrent exertional syncope/presyncope despite maximally tolerated medical therapy.
- Hemodynamic Gradient Threshold: Dynamic LVOT peak instantaneous gradient of 50 mmHg or greater at rest or with physiological provocation (Valsalva, standing, or upright exercise echocardiography) associated with SAM-mediated obstruction.
- Anatomical Septal Thickness: Basal anterior septal thickness sufficient to safely perform the procedure (typically 15 to 16 mm or greater).
- Strict Contraindication (Class III — Harm): Septal reduction therapy (ASA or surgical myectomy) must NOT be performed in asymptomatic patients or in patients whose symptoms are well controlled on medical therapy, regardless of the magnitude of the resting or provoked LVOT gradient.
- The “Cardiac Myosin Inhibitor First” Shift (2024 AHA/ACC & 2023 ESC Guidelines):
- Step 1 (First-Line Medical Therapy — Class I): Non-vasodilating Beta-Blockers (titrated to resting HR <60 to 65 bpm) or Non-Dihydropyridine Calcium Channel Blockers (Verapamil or Diltiazem).
- Step 2 (Refractory Symptoms — Class I Equal Options in 2024 AHA/ACC): For patients remaining symptomatic on Step 1 therapy, the 2024 AHA/ACC HCM Guidelines elevate Cardiac Myosin Inhibitors (Mavacamten; Aficamten has since been studied in SEQUOIA-HCM), Disopyramide, and Septal Reduction Therapy (Surgical Myectomy or ASA at an experienced center) as Class I options based on shared decision-making.
- Landmark VALOR-HCM Trial (JACC 2022 / Circulation 2023): Randomized HOCM patients already referred and guideline-eligible for SRT (Myectomy or ASA) to Mavacamten vs. Placebo; at 16 and 56 weeks, more than 80 to 89 percent of patients treated with Mavacamten no longer met guideline criteria for SRT and chose not to undergo invasive ASA or surgery—repositioning ASA in clinical practice to patients who fail, are intolerant of, or cannot afford/access myosin inhibitors, or who prefer a one-time procedural intervention over lifelong REMS echocardiographic monitoring.
- Guideline Class of Recommendation for ASA (Class I, Level B-NR): In eligible adult HOCM patients in whom Surgical Septal Myectomy is contraindicated or carries high risk due to advanced age, frailty, or serious comorbidities (or who prefer a percutaneous approach after shared decision-making), ASA is Class I recommended when performed at a Comprehensive HCM Center.
IISTEPWISE PROCEDURAL TECHNIQUE AND MANDATORY CONTRAST ECHO GUIDANCE
- Pre-Procedural Cardiac CT Angiography Planning: High-resolution Coronary CTA maps the origin, caliber, angulation, and myocardial perfusion territory of the first and second septal perforator arteries (which arise from the proximal LAD in >90% of cases, or occasionally from a diagonal, ramus, or RCA/PDA) and measures basal septal thickness.
- Temporary Pacemaker Placement and Baseline Hemodynamics: A temporary transvenous pacemaker lead is placed in the right ventricular apex (ideally an active-fixation screw-in lead via the internal jugular vein if baseline LBBB is present, given the >50% risk of complete heart block), and simultaneous LV apex (via a transaortic pigtail without side-holes) and ascending aortic pressures are recorded at rest, after a premature ventricular contraction (Brockenbrough-Braunwald-Morrow sign), and during Valsalva.
- Over-the-Wire (OTW) Balloon Occlusion of the Target Septal Perforator: A short compliant Over-the-Wire (OTW) angioplasty balloon (1.5 to 2.5 mm) is inflated at low pressure (4 to 6 atm) in the proximal target septal perforator. Complete balloon occlusion is mandatory to prevent catastrophic retrograde reflux of absolute alcohol back into the main LAD (which causes massive anterior STEMI).
- Mandatory Myocardial Contrast Echocardiography (MCE — The Safety Cornerstone):
- Technique: Before any alcohol is drawn up, 1 to 2 mL of ultrasound contrast agent (or agitated radiographic contrast/gelatin) is injected strictly through the central lumen of the inflated OTW balloon during continuous Transthoracic Echocardiography (TTE) in the apical 4-, 3-, and parasternal views.
- Confirmation Criteria: MCE must confirm that contrast opacification is restricted exclusively to the basal interventricular septum directly encompassing the exact point of mitral leaflet-septal (SAM) contact.
- Absolute Abort Criteria: If MCE shows contrast enhancing the Left Ventricular free wall, apex, papillary muscles, or the Right Ventricular free wall / moderator band, alcohol must NOT be injected into that branch (the balloon is deflated and a different septal sub-branch is wired), preventing non-target infarction, papillary muscle rupture/severe MR, or large VSD.
- Low-Dose Desiccated Ethanol Infusion: Once MCE confirms the exact basal SAM contact zone (and balloon occlusion alone often produces an immediate stunned drop in the LVOT gradient), desiccated 96–98% ethanol is infused slowly (0.08 to 0.1 mL per millimeter of basal septal thickness; typically 1.0 to 2.0 mL total, significantly lower than historical 3 to 5 mL doses, which reduces complete heart block rates without sacrificing efficacy) over 3 to 5 minutes. The balloon is kept inflated for 10 minutes after flushing with saline so all ethanol fixes in the tissue before balloon deflation.
- Bimodal (“Triphasic”) Gradient Response: The LVOT gradient drops immediately in the cath lab (due to acute myocardial stunning/akinesia), frequently rebounds transiently at Days 2 to 5 (due to acute localized myocardial edema swelling the infarcted basal septum), and then progressively declines over 3 to 12 months as collagen scar contraction thins and remodels the basal septum.
IIIALCOHOL SEPTAL ABLATION VS. SURGICAL EXTENDED MYECTOMY (MORROW PROCEDURE)
| Clinical / Anatomical Parameter | Alcohol Septal Ablation (ASA) | Extended Surgical Septal Myectomy (Morrow) |
|---|---|---|
| Procedural Approach & Recovery | Percutaneous femoral/radial catheter; hospital stay 2–4 days | Median sternotomy + cardiopulmonary bypass; hospital stay 5–7 days |
| Mechanism of LVOT Relief | Coronary anatomy-dependent coagulative necrosis -> scar thinning over 3–12 months | Direct visual muscular resection -> immediate abolition of gradient |
| Typical Conduction Defect Induced | Right Bundle Branch Block (RBBB) in 50–60% (high CHB risk if baseline LBBB exists) | Left Bundle Branch Block (LBBB) in 40–50% (high CHB risk if baseline RBBB exists) |
| Permanent Pacemaker (PPM) Rate | Higher: 8% to 12% (up to 15–20% in elderly or baseline LBBB) | Lower: 2% to 5% (higher if baseline RBBB exists) |
| Residual Gradient & Repeat SRT Rate | Higher repeat ablation/myectomy rate: 7% to 12% | Very low repeat intervention rate: <1% to 2% |
| Long-Term Survival & SCD Risk | Comparable 10-year survival to myectomy in matched cohorts; no proven excess SCD when low alcohol dose (<2 mL) is used | Gold standard for children, young adults (<40–50 yr), massive LVH (>=30 mm), mid-cavitary obstruction, or intrinsic MV/papillary anomalies |
IVWHEN SURGICAL SEPTAL MYECTOMY IS STRICTLY PREFERRED OVER ASA (CLASS I)
- Children and Young Adults: Surgical myectomy is preferred in children and young adults due to superior single-procedure durability and lower lifetime pacemaker dependency.
- Massive Basal Septal Hypertrophy (30 mm or Greater): ASA cannot reliably penetrate or thin a >30 mm septum.
- Concomitant Intrinsic Mitral Valve or Subvalvular Apparatus Abnormalities: Ruptured chordae, intrinsic degenerative mitral prolapse, markedly elongated anterior mitral leaflet (>30 mm) requiring surgical leaflet plication, or anomalous papillary muscle inserting directly into the mitral body/LVOT (where alcohol ablation of the septum alone will fail to abolish LVOT obstruction).
- Mid-Cavitary or Apical Obstruction: Supplied by distal LAD/diagonal branches rather than proximal septal perforators.
- Concomitant Surgical Lesions: Multivessel Coronary Artery Disease requiring CABG, Aortic Stenosis, or Atrial Fibrillation warranting surgical Maze + LAA exclusion.
- Absence of a Suitable Septal Perforator Artery: Present in 5 to 10 percent of patients (or when MCE demonstrates exclusively non-target RV/papillary muscle perfusion).
VCOMPLICATIONS AND THE BUNDLE-BRANCH CROSS-MATCH RULE
- The Bundle-Branch “Cross-Match” Exam Rule for Complete Heart Block (CHB):
- ASA damages the Right Bundle Branch (producing RBBB in 50 to 60 percent) because the right bundle courses subendocardially down the right side of the basal interventricular septum supplied by the first septal perforator. Therefore, a patient with pre-existing baseline LBBB undergoing ASA has a >50 to 70 percent risk of developing Complete Heart Block.
- Conversely, Surgical Septal Myectomy damages the Left Bundle Branch (producing LBBB in 40 to 50 percent) because the surgical excision is performed on the left ventricular subaortic aspect of the septum. Therefore, a patient with pre-existing baseline RBBB undergoing Surgical Myectomy has a high risk of developing Complete Heart Block.
- Other Procedural Complications: LAD dissection or acute anterior wall MI from alcohol reflux (<1%, prevented by OTW balloon occlusion check), distant RV/papillary muscle infarction (prevented by mandatory MCE), sustained ventricular arrhythmias during the acute 48-hour ischemic phase (~2–5%, mandating 48 to 72 hours of ICU telemetry), and rare iatrogenic Ventricular Septal Defect.
Key references
- Ommen SR, Ho CY, Asif IM, et al.: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy, Circulation / Journal of the American College of Cardiology, 2024.
- Arbelo E, Protonotarios A, Gimeno JR, et al.: 2023 ESC Guidelines for the management of cardiomyopathies, European Heart Journal, 2023.
- Desai MY, Owens A, Geske JB, et al. (VALOR-HCM Investigators): Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy, Journal of the American College of Cardiology, 2022.
- Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H: Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy, Journal of the American College of Cardiology, 2018.
meritmedscript.comDr. Sidhartha Mullapudi
